NeuroMetrix (NASDAQ:NURO) Shares Pass Above 200 Day Moving Average of $3.70

NeuroMetrix, Inc. (NASDAQ:NUROGet Free Report)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.70 and traded as high as $3.86. NeuroMetrix shares last traded at $3.75, with a volume of 3,143 shares traded.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on NeuroMetrix in a research report on Wednesday. They set a “sell” rating for the company.

Check Out Our Latest Research Report on NURO

NeuroMetrix Stock Performance

The firm has a market cap of $7.54 million, a P/E ratio of -0.60 and a beta of 2.16. The company has a 50-day moving average of $4.08 and a 200 day moving average of $3.70.

Institutional Investors Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Cerity Partners LLC purchased a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NUROFree Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned approximately 2.80% of NeuroMetrix at the end of the most recent reporting period. 19.40% of the stock is owned by institutional investors and hedge funds.

NeuroMetrix Company Profile

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.

Featured Articles

Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.